{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T01:56:20Z","timestamp":1780624580407,"version":"3.54.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T00:00:00Z","timestamp":1601942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T00:00:00Z","timestamp":1601942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010621","name":"Uniwersytet Medyczny w Lublinie","doi-asserted-by":"publisher","award":["DS 474 \/ 2012-2015"],"award-info":[{"award-number":["DS 474 \/ 2012-2015"]}],"id":[{"id":"10.13039\/501100010621","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010621","name":"Medical University of Lublin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100010621","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Combination therapy consisting of two or more antiepileptic drugs (AEDs) is usually prescribed for patients with refractory epilepsy. The drug\u2013drug interactions, which may occur among currently available AEDs, are the principal criterion taken by physicians when prescribing the AED combination to the patients. Unfortunately, the number of possible three-drug combinations tremendously increases along with the clinical approval of novel AEDs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Aim<\/jats:title>\n                <jats:p>To isobolographically characterize three-drug interactions of phenobarbital (PB) with lamotrigine (LTG), oxcarbazepine (OXC), pregabalin (PGB) and topiramate (TPM), the maximal electroshock-induced (MES) seizure model was used in male albino Swiss mice.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and method<\/jats:title>\n                <jats:p>The MES-induced seizures in mice were generated by alternating current delivered via auricular electrodes. To classify interactions for 6 various three-drug combinations of AEDs (i.e., PB\u2009+\u2009TPM\u2009+\u2009PGB, PB\u2009+\u2009OXC\u2009+\u2009TPM, PB\u2009+\u2009LTG\u2009+\u2009TPM, PB\u2009+\u2009OXC\u2009+\u2009PGB, PB\u2009+\u2009LTG\u2009+\u2009PGB and PB\u2009+\u2009LTG\u2009+\u2009OXC), the type I isobolographic analysis was used. Total brain concentrations of PB were measured by fluorescent polarization immunoassay technique.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The three-drug mixtures of PB\u2009+\u2009TPM\u2009+\u2009PGB, PB\u2009+\u2009OXC\u2009+\u2009TPM, PB\u2009+\u2009LTG\u2009+\u2009TPM, PB\u2009+\u2009OXC\u2009+\u2009PGB, PB\u2009+\u2009LTG\u2009+\u2009PGB and PB\u2009+\u2009LTG\u2009+\u2009OXC protected the male albino Swiss mice from MES-induced seizures. All the observed interactions in this seizure model were supra-additive (synergistic) (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), except for the combination of PB\u2009+\u2009LTG\u2009+\u2009OXC, which was additive. It was unable to show the impact of the studied second-generation AEDs on total brain content of PB in mice.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The synergistic interactions among PB and LTG, OXC, PGB and TPM in the mouse MES model are worthy of being transferred to clinical trials, especially for the patients with drug resistant epilepsy, who would benefit these treatment options.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s43440-020-00164-5","type":"journal-article","created":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T23:04:29Z","timestamp":1602025469000},"page":"111-121","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Polygonogram with isobolographic synergy for three-drug combinations of phenobarbital with second-generation antiepileptic drugs in the tonic\u2013clonic seizure model in mice"],"prefix":"10.1007","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3059-0393","authenticated-orcid":false,"given":"Jarogniew J.","family":"\u0141uszczki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominika","family":"Podg\u00f3rska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8817-5638","authenticated-orcid":false,"given":"Justyna","family":"Kozi\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9900-9168","authenticated-orcid":false,"given":"Marek","family":"Jankiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6255-5085","authenticated-orcid":false,"given":"Zbigniew","family":"Plewa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4591-6752","authenticated-orcid":false,"given":"Mateusz","family":"Kominek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1988-0119","authenticated-orcid":false,"given":"Dorota","family":"\u017b\u00f3\u0142kowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1489-2399","authenticated-orcid":false,"given":"Magdalena","family":"Florek-\u0141uszczki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,6]]},"reference":[{"key":"164_CR1","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.eplepsyres.2017.07.011","volume":"136","author":"E Martinez-Lizana","year":"2017","unstructured":"Martinez-Lizana E, Gil-Lopez F, Donaire A, Aparicio J, Brandt A, Carreno M. Outcome of treatment changes in patients with drug-resistant chronic epilepsy: a tertiary center experience. Epilepsy Res. 2017;136:97\u2013102.","journal-title":"Epilepsy Res"},{"key":"164_CR2","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","volume":"51","author":"P Kwan","year":"2010","unstructured":"Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE commission on therapeutic strategies. Epilepsia. 2010;51:1069\u201377.","journal-title":"Epilepsia"},{"key":"164_CR3","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1080\/14737175.2020.1707668","volume":"20","author":"A Verrotti","year":"2020","unstructured":"Verrotti A, Tambucci R, Di Francesco L, Pavone P, Iapadre G, Altobelli E, et al. The role of polytherapy in the management of epilepsy: suggestions for rational antiepileptic drug selection. Expert Rev Neurother. 2020;20:167\u201373.","journal-title":"Expert Rev Neurother"},{"key":"164_CR4","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/978-94-017-8914-1_24","volume":"813","author":"M Barker-Haliski","year":"2014","unstructured":"Barker-Haliski M, Sills GJ, White HS. What are the arguments for and against rational therapy for epilepsy? Adv Exp Med Biol. 2014;813:295\u2013308.","journal-title":"Adv Exp Med Biol"},{"key":"164_CR5","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.seizure.2011.01.004","volume":"20","author":"MJ Brodie","year":"2011","unstructured":"Brodie MJ, Sills GJ. Combining antiepileptic drugs\u2013rational polytherapy? Seizure. 2011;20:369\u201375.","journal-title":"Seizure"},{"key":"164_CR6","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.2147\/NDT.S84852","volume":"12","author":"L Dalic","year":"2016","unstructured":"Dalic L, Cook MJ. Managing drug-resistant epilepsy: challenges and solutions. Neuropsych Disease Treat. 2016;12:2605\u201316.","journal-title":"Neuropsych Disease Treat"},{"issue":"Suppl 4","key":"164_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/epi.12294","volume":"54","author":"JA French","year":"2013","unstructured":"French JA, White HS, Klitgaard H, Holmes GL, Privitera MD, Cole AJ, et al. Development of new treatment approaches for epilepsy: unmet needs and opportunities. Epilepsia. 2013;54(Suppl 4):3\u201312.","journal-title":"Epilepsia"},{"key":"164_CR8","first-page":"31","volume":"162","author":"E Perucca","year":"1995","unstructured":"Perucca E. Pharmacological principles as a basis for polytherapy. Acta Neurol Scand Suppl. 1995;162:31\u20134.","journal-title":"Acta Neurol Scand Suppl"},{"key":"164_CR9","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/0140-6736(93)91062-Q","volume":"341","author":"F Pisani","year":"1993","unstructured":"Pisani F, Di Perri R, Perucca E, Richens A. Interaction of lamotrigine with sodium valproate. Lancet. 1993;341:1224.","journal-title":"Lancet"},{"key":"164_CR10","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1053\/seiz.2002.0711","volume":"11","author":"LJ Stephen","year":"2002","unstructured":"Stephen LJ, Brodie MJ. Seizure freedom with more than one antiepileptic drug. Seizure. 2002;11:349\u201351.","journal-title":"Seizure"},{"key":"164_CR11","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1097\/WCO.0b013e328350ba68","volume":"25","author":"LJ Stephen","year":"2012","unstructured":"Stephen LJ, Brodie MJ. Antiepileptic drug monotherapy versus polytherapy: pursuing seizure freedom and tolerability in adults. Curr Opin Neurol. 2012;25:164\u201372.","journal-title":"Curr Opin Neurol"},{"key":"164_CR12","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.eplepsyres.2011.09.008","volume":"98","author":"LJ Stephen","year":"2012","unstructured":"Stephen LJ, Forsyth M, Kelly K, Brodie MJ. Antiepileptic drug combinations\u2013have newer agents altered clinical outcomes? Epilepsy Res. 2012;98:194\u20138.","journal-title":"Epilepsy Res"},{"key":"164_CR13","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1111\/j.1528-1157.2000.tb00111.x","volume":"41","author":"CL Deckers","year":"2000","unstructured":"Deckers CL, Czuczwar SJ, Hekster YA, Keyser A, Kubova H, Meinardi H, et al. Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed. Epilepsia. 2000;41:1364\u201374.","journal-title":"Epilepsia"},{"key":"164_CR14","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.2165\/00003495-200666140-00004","volume":"66","author":"P Kwan","year":"2006","unstructured":"Kwan P, Brodie MJ. Combination therapy in epilepsy: when and what to use. Drugs. 2006;66:1817\u201329.","journal-title":"Drugs"},{"key":"164_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.eplepsyres.2003.08.003","volume":"56","author":"JJ Luszczki","year":"2003","unstructured":"Luszczki JJ, Czuczwar SJ. Isobolographic and subthreshold methods in the detection of interactions between oxcarbazepine and conventional antiepileptics\u2013a comparative study. Epilepsy Res. 2003;56:27\u2013422.","journal-title":"Epilepsy Res"},{"key":"164_CR16","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1111\/j.0013-9580.2004.05104.x","volume":"45","author":"JJ Luszczki","year":"2004","unstructured":"Luszczki JJ, Czuczwar SJ. Preclinical profile of combinations of some second-generation antiepileptic drugs: an isobolographic analysis. Epilepsia. 2004;45:895\u2013907.","journal-title":"Epilepsia"},{"key":"164_CR17","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.ejphar.2014.08.001","volume":"741","author":"N Matsumura","year":"2014","unstructured":"Matsumura N, Nakaki T. Isobolographic analysis of the mechanisms of action of anticonvulsants from a combination effect. Eur J Pharmacol. 2014;741:237\u201346.","journal-title":"Eur J Pharmacol"},{"key":"164_CR18","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.eplepsyres.2017.02.020","volume":"132","author":"J Makinen","year":"2017","unstructured":"Makinen J, Rainesalo S, Raitanen J, Peltola J. The effect of newer antiepileptic drugs in combination therapy. Epilepsy Res. 2017;132:15\u201320.","journal-title":"Epilepsy Res"},{"key":"164_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s43440-020-00117-y","author":"JJ Luszczki","year":"2020","unstructured":"Luszczki JJ, Kondrat-Wr\u00f3bel M, Zagaja M, Karwan S, Bojar H, Plewa Z, et al. Sub-additive (antagonistic) interaction of lacosamide with lamotrigine and valproate in the maximal electroshock-induced seizure model in mice: an isobolographic analysis. Pharmacol Rep. 2020. https:\/\/doi.org\/10.1007\/s43440-020-00117-y.","journal-title":"Pharmacol Rep"},{"key":"164_CR20","doi-asserted-by":"publisher","first-page":"92","DOI":"10.5114\/hpc.2019.81105","volume":"13","author":"MW Kondrat-Wr\u00f3bel","year":"2019","unstructured":"Kondrat-Wr\u00f3bel MW, Za\u0142uska K, Walczak A, Panasiuk-Poterek AN, Gut-Lepiech A, Wr\u00f3blewska-\u0141uczka P, et al. Antagonistic interaction of lacosamide with carbamazepine and valproate in the mouse tonic-clonic seizure model. Health Probl Civiliz. 2019;13:92\u20138.","journal-title":"Health Probl Civiliz"},{"key":"164_CR21","doi-asserted-by":"publisher","first-page":"303","DOI":"10.15584\/ejcem.2017.4.1","volume":"15","author":"MW Kondrat-Wrobel","year":"2017","unstructured":"Kondrat-Wrobel MW, Luszczki JJ. Additive interaction for three-drug combination of carbamazepine, lacosamide and lamotrigine against maximal electroshock-induced seizures\u2014a type I isobolographic analysis. Eur J Clin Exp Med. 2017;15:303\u20139.","journal-title":"Eur J Clin Exp Med"},{"key":"164_CR22","doi-asserted-by":"publisher","first-page":"55","DOI":"10.5114\/hpc.2016.58209","volume":"10","author":"MW Kondrat-Wrobel","year":"2016","unstructured":"Kondrat-Wrobel MW, Luszczki JJ. Interaction of three-drug combination of lacosamide, carbamazepine and phenobarbital in the mouse maximal electroshock-induced seizure model\u2014an isobolographic analysis. Health Probl Civiliz. 2016;10:55\u201361.","journal-title":"Health Probl Civiliz"},{"key":"164_CR23","doi-asserted-by":"publisher","first-page":"881","DOI":"10.17219\/acem\/69132","volume":"27","author":"MW Kondrat-Wrobel","year":"2018","unstructured":"Kondrat-Wrobel MW, Luszczki JJ. Isobolographic additivity among lacosamide, lamotrigine and phenobarbital in the mouse tonic-clonic seizure model. Adv Clin Exp Med. 2018;27:881\u20136.","journal-title":"Adv Clin Exp Med"},{"key":"164_CR24","doi-asserted-by":"publisher","first-page":"72","DOI":"10.26444\/jpccr\/109381","volume":"13","author":"K Za\u0142uska","year":"2019","unstructured":"Za\u0142uska K, Marz\u0119da P, Bojar H, Walczak A, Chmielewski J, Wr\u00f3blewska-\u0141uczka P, et al. Additive suppression of tonic-clonic seizures in mice receiving the combination of carbamazepine, phenobarbital and valproate. J Pre-Clin Clin Res. 2019;13:72\u20135.","journal-title":"J Pre-Clin Clin Res"},{"key":"164_CR25","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1159\/000444452","volume":"97","author":"JJ Luszczki","year":"2016","unstructured":"Luszczki JJ. Isobolographic analysis of interaction for three-drug combination of carbamazepine, phenobarbital and topiramate in the mouse maximal electroshock-induced seizure model. Pharmacology. 2016;97:259\u201364.","journal-title":"Pharmacology"},{"key":"164_CR26","doi-asserted-by":"publisher","first-page":"111","DOI":"10.26444\/jpccr\/101578","volume":"12","author":"K Za\u0142uska","year":"2018","unstructured":"Za\u0142uska K, Kondrat-Wr\u00f3bel MW, Panasiuk-Poterek AN, Marz\u0119da P, Walczak A, Wr\u00f3blewska-\u0141uczka P, et al. Synergy among oxcarbazepine, pregabalin and topiramate in the mouse maximal electroshock induced seizure test\u2014an isobolographic analysis. J Pre-Clin Clin Res. 2018;12:111\u20136.","journal-title":"J Pre-Clin Clin Res"},{"key":"164_CR27","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.eplepsyres.2018.06.003","volume":"145","author":"JJ Luszczki","year":"2018","unstructured":"Luszczki JJ, Mazurkiewicz LP, Wroblewska-Luczka P, Wlaz A, Ossowska G, Szpringer M, et al. Combination of phenobarbital with phenytoin and pregabalin produces synergy in the mouse tonic-clonic seizure model: an isobolographic analysis. Epilepsy Res. 2018;145:116\u201322.","journal-title":"Epilepsy Res"},{"key":"164_CR28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2174\/1568026053386962","volume":"5","author":"P Czapinski","year":"2005","unstructured":"Czapinski P, Blaszczyk B, Czuczwar SJ. Mechanisms of action of antiepileptic drugs. Curr Top Med Chem. 2005;5:3\u201314.","journal-title":"Curr Top Med Chem"},{"key":"164_CR29","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s11910-008-0053-7","volume":"8","author":"MA Rogawski","year":"2008","unstructured":"Rogawski MA, Bazil CW. New molecular targets for antiepileptic drugs: alpha(2)delta, SV2A, and K(v)7\/KCNQ\/M potassium channels. Curr Neurol Neurosci Rep. 2008;8:345\u201352.","journal-title":"Curr Neurol Neurosci Rep"},{"key":"164_CR30","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/0920-1211(91)90075-Q","volume":"8","author":"W Loscher","year":"1991","unstructured":"Loscher W, Fassbender CP, Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. II Maximal electroshock seizure models. Epilepsy Res. 1991;8:79\u201394.","journal-title":"Epilepsy Res"},{"key":"164_CR31","volume-title":"The Epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care: pharmacological update of clinical guideline 20","author":"National Clinical Guideline C. National Institute for Health and Clinical Excellence: Guidance","year":"2012","unstructured":"National Clinical Guideline C. National Institute for Health and Clinical Excellence: Guidance. The Epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care: pharmacological update of clinical guideline 20. London: Royal College of Physicians (UK) National Clinical Guideline Centre; 2012."},{"key":"164_CR32","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s00210-007-0144-z","volume":"375","author":"JJ Luszczki","year":"2007","unstructured":"Luszczki JJ. Isobolographic analysis of interaction between drugs with nonparallel dose-response relationship curves: a practical application. Naunyn Schmiedebergs Arch Pharmacol. 2007;375:105\u201314.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"164_CR33","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s00210-008-0349-9","volume":"379","author":"JJ Luszczki","year":"2009","unstructured":"Luszczki JJ, Wu JZ, Raszewski G, Czuczwar SJ. Isobolographic characterization of interactions of retigabine with carbamazepine, lamotrigine, and valproate in the mouse maximal electroshock-induced seizure model. Naunyn Schmiedebergs Arch Pharmacol. 2009;379:163\u201379.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"164_CR34","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.eplepsyres.2010.01.001","volume":"89","author":"JJ Luszczki","year":"2010","unstructured":"Luszczki JJ, Antkiewicz-Michaluk L, Raszewski G, Czuczwar SJ. Interactions of 1-methyl-1,2,3,4-tetrahydroisoquinoline with lamotrigine, oxcarbazepine, pregabalin, and topiramate in the mouse maximal electroshock-induced seizure model: a type I isobolographic analysis. Epilepsy Res. 2010;89:207\u201319.","journal-title":"Epilepsy Res"},{"key":"164_CR35","first-page":"99","volume":"96","author":"JT Litchfield Jr","year":"1949","unstructured":"Litchfield JT Jr, Wilcoxon F. A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther. 1949;96:99\u2013113.","journal-title":"J Pharmacol Exp Ther"},{"key":"164_CR36","doi-asserted-by":"publisher","first-page":"609","DOI":"10.17219\/acem\/68694","volume":"27","author":"K Zaluska","year":"2018","unstructured":"Zaluska K, Kondrat-Wrobel MW, Luszczki JJ. Comparison of the anticonvulsant potency of various diuretic drugs in the maximal electroshock-induced seizure threshold test in mice. Adv Clin Exp Med. 2018;27:609\u201313.","journal-title":"Adv Clin Exp Med"},{"key":"164_CR37","first-page":"285","volume":"3","author":"S Loewe","year":"1953","unstructured":"Loewe S. The problem of synergism and antagonism of combined drugs. Arzneimittelforschung. 1953;3:285\u201390.","journal-title":"Arzneimittelforschung"},{"key":"164_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1124\/jpet.106.104117","volume":"319","author":"RJ Tallarida","year":"2006","unstructured":"Tallarida RJ. An overview of drug combination analysis with isobolograms. J Pharmacol Exp Ther. 2006;319:1\u20137.","journal-title":"J Pharmacol Exp Ther"},{"key":"164_CR39","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s00210-006-0055-4","volume":"373","author":"JJ Luszczki","year":"2006","unstructured":"Luszczki JJ, Ratnaraj N, Patsalos PN, Czuczwar SJ. Isobolographic analysis of interactions between loreclezole and conventional antiepileptic drugs in the mouse maximal electroshock-induced seizure model. Naunyn Schmiedebergs Arch Pharmacol. 2006;373:169\u201381.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"164_CR40","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1046\/j.1528-1157.2003.32702.x","volume":"44","author":"JJ Luszczki","year":"2003","unstructured":"Luszczki JJ, Borowicz KK, Swiader M, Czuczwar SJ. Interactions between oxcarbazepine and conventional antiepileptic drugs in the maximal electroshock test in mice: an isobolographic analysis. Epilepsia. 2003;44:489\u201399.","journal-title":"Epilepsia"},{"key":"164_CR41","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1474-4422(03)00409-5","volume":"2","author":"PN Patsalos","year":"2003","unstructured":"Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol. 2003;2:347\u201356.","journal-title":"Lancet Neurol"},{"key":"164_CR42","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1080\/17512433.2018.1500895","volume":"11","author":"B Blaszczyk","year":"2018","unstructured":"Blaszczyk B, Miziak B, Czuczwar P, Wierzchowska-Cioch E, Pluta R, Czuczwar SJ. A viewpoint on rational and irrational fixed-drug combinations. Exp Rev Clin Pharmacol. 2018;11:761.","journal-title":"Exp Rev Clin Pharmacol"},{"key":"164_CR43","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1124\/jpet.109.153908","volume":"330","author":"MF Braga","year":"2009","unstructured":"Braga MF, Aroniadou-Anderjaska V, Li H, Rogawski MA. Topiramate reduces excitability in the basolateral amygdala by selectively inhibiting GluK1 (GluR5) kainate receptors on interneurons and positively modulating GABAA receptors on principal neurons. J Pharmacol Exp Ther. 2009;330:558\u201366.","journal-title":"J Pharmacol Exp Ther"},{"key":"164_CR44","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1007\/s00702-017-1771-2","volume":"124","author":"M Motaghinejad","year":"2017","unstructured":"Motaghinejad M, Motevalian M, Fatima S, Beiranvand T, Mozaffari S. Topiramate via NMDA, AMPA\/kainate, GABAA and Alpha2 receptors and by modulation of CREB\/BDNF and Akt\/GSK3 signaling pathway exerts neuroprotective effects against methylphenidate-induced neurotoxicity in rats. J Neural Transm. 2017;124:1369\u201387.","journal-title":"J Neural Transm"},{"key":"164_CR45","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1111\/j.1528-1157.2000.tb02163.x","volume":"41","author":"RP Shank","year":"2000","unstructured":"Shank RP, Gardocki JF, Streeter AJ, Maryanoff BE. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia. 2000;41:S3\u20139.","journal-title":"Epilepsia"},{"key":"164_CR46","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1007\/s11064-015-1749-0","volume":"41","author":"M Sitges","year":"2016","unstructured":"Sitges M, Chiu LM, Reed RC. Effects of levetiracetam, carbamazepine, phenytoin, valproate, lamotrigine, oxcarbazepine, topiramate, vinpocetine and sertraline on presynaptic hippocampal Na(+) and Ca(2+) channels permeability. Neurochem Res. 2016;41:758\u201369.","journal-title":"Neurochem Res"},{"issue":"Suppl 5","key":"164_CR47","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1111\/j.1528-1157.1999.tb00913.x","volume":"40","author":"HS White","year":"1999","unstructured":"White HS. Comparative anticonvulsant and mechanistic profile of the established and newer antiepileptic drugs. Epilepsia. 1999;40(Suppl 5):S2\u201310.","journal-title":"Epilepsia"},{"key":"164_CR48","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/0300-483X(95)03210-7","volume":"105","author":"PK Gessner","year":"1995","unstructured":"Gessner PK. Isobolographic analysis of interactions: an update on applications and utility. Toxicology. 1995;105:161\u201379.","journal-title":"Toxicology"},{"key":"164_CR49","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S0304-3959(02)00041-6","volume":"98","author":"RJ Tallarida","year":"2002","unstructured":"Tallarida RJ. The interaction index: a measure of drug synergism. Pain. 2002;98:163\u20138.","journal-title":"Pain"},{"key":"164_CR50","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1080\/10428190802353591","volume":"49","author":"TC Chou","year":"2008","unstructured":"Chou TC. Preclinical versus clinical drug combination studies. Leuk Lymphoma. 2008;49:2059\u201380.","journal-title":"Leuk Lymphoma"},{"key":"164_CR51","first-page":"925","volume":"1","author":"TC Chou","year":"2011","unstructured":"Chou TC. The mass-action law based algorithm for cost-effective approach for cancer drug discovery and development. Am J Cancer Res. 2011;1:925\u201354.","journal-title":"Am J Cancer Res"},{"key":"164_CR52","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.phrs.2016.03.016","volume":"107","author":"L Santulli","year":"2016","unstructured":"Santulli L, Coppola A, Balestrini S, Striano S. The challenges of treating epilepsy with 25 antiepileptic drugs. Pharmacol Res. 2016;107:211\u20139.","journal-title":"Pharmacol Res"},{"key":"164_CR53","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1046\/j.1528-1157.2003.10003.x","volume":"44","author":"JJ Luszczki","year":"2003","unstructured":"Luszczki JJ, Czuczwar M, Kis J, Krysa J, Pasztelan I, Swiader M, et al. Interactions of lamotrigine with topiramate and first-generation antiepileptic drugs in the maximal electroshock test in mice: an isobolographic analysis. Epilepsia. 2003;44:1003\u201313.","journal-title":"Epilepsia"},{"key":"164_CR54","first-page":"103","volume":"3","author":"JJ Luszczki","year":"2009","unstructured":"Luszczki JJ. Interactions between pregabalin and phenobarbital in the mouse maximal electroshock-induced seizure model: an isobolographic analysis. J Pre-Clin Clin Res. 2009;3:103\u20139.","journal-title":"J Pre-Clin Clin Res"},{"key":"164_CR55","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.eplepsyres.2010.07.009","volume":"91","author":"JJ Luszczki","year":"2010","unstructured":"Luszczki JJ, Filip D, Czuczwar SJ. Additive interactions of pregabalin with lamotrigine, oxcarbazepine and topiramate in the mouse maximal electroshock-induced seizure model: a type I isobolographic analysis for non-parallel dose-response relationship curves. Epilepsy Res. 2010;91:166\u201375.","journal-title":"Epilepsy Res"},{"key":"164_CR56","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1517\/17425255.2013.749239","volume":"9","author":"A Schulze-Bonhage","year":"2013","unstructured":"Schulze-Bonhage A. Pharmacokinetic and pharmacodynamic profile of pregabalin and its role in the treatment of epilepsy. Expert Opin Drug Metab Toxicol. 2013;9:105\u201315.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"164_CR57","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/bcp.12984","volume":"82","author":"D Milosheska","year":"2016","unstructured":"Milosheska D, Lorber B, Vovk T, Kastelic M, Dolzan V, Grabnar I. Pharmacokinetics of lamotrigine and its metabolite N-2-glucuronide: Influence of polymorphism of UDP-glucuronosyltransferases and drug transporters. Br J Clin Pharmacol. 2016;82:399\u2013411.","journal-title":"Br J Clin Pharmacol"},{"key":"164_CR58","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1111\/bcp.13392","volume":"83","author":"C Rodrigues","year":"2017","unstructured":"Rodrigues C, Chiron C, Rey E, Dulac O, Comets E, Pons G, et al. Population pharmacokinetics of oxcarbazepine and its monohydroxy derivative in epileptic children. Br J Clin Pharmacol. 2017;83:2695\u2013708.","journal-title":"Br J Clin Pharmacol"},{"key":"164_CR59","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1097\/FTD.0000000000000546","volume":"40","author":"PN Patsalos","year":"2018","unstructured":"Patsalos PN, Spencer EP, Berry DJ. Therapeutic drug monitoring of antiepileptic drugs in epilepsy: a 2018 update. Therap Drug Monit. 2018;40:526\u201348.","journal-title":"Therap Drug Monit"},{"key":"164_CR60","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/S1474-4422(03)00483-6","volume":"2","author":"PN Patsalos","year":"2003","unstructured":"Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol. 2003;2:473\u201381.","journal-title":"Lancet Neurol"},{"key":"164_CR61","first-page":"1","volume-title":"Guideline on the investigation of bioequivalence","author":"Committee for medicinal products for human use","year":"2010","unstructured":"Committee for medicinal products for human use. Guideline on the investigation of bioequivalence. London: European Medicines Agency; 2010. p. 1\u201327."},{"key":"164_CR62","doi-asserted-by":"publisher","first-page":"107811","DOI":"10.1016\/j.neuropharm.2019.107811","volume":"166","author":"KS Wilcox","year":"2020","unstructured":"Wilcox KS, West PJ, Metcalf CS. The current approach of the epilepsy therapy screening program contract site for identifying improved therapies for the treatment of pharmacoresistant seizures in epilepsy. Neuropharmacology. 2020;166:107811.","journal-title":"Neuropharmacology"},{"key":"164_CR63","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.seizure.2011.01.003","volume":"20","author":"W Loscher","year":"2011","unstructured":"Loscher W. Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs. Seizure. 2011;20:359\u201368.","journal-title":"Seizure"},{"key":"164_CR64","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.yebeh.2015.02.027","volume":"49","author":"W Loscher","year":"2015","unstructured":"Loscher W. Single versus combinatorial therapies in status epilepticus: novel data from preclinical models. Epilepsy Behav. 2015;49:20\u20135.","journal-title":"Epilepsy Behav"},{"key":"164_CR65","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1007\/s11064-016-2025-7","volume":"42","author":"W Loscher","year":"2016","unstructured":"Loscher W. The search for new screening models of pharmacoresistant epilepsy: is induction of acute seizures in epileptic rodents a suitable approach? Neurochem Res. 2016;42:1926\u201338.","journal-title":"Neurochem Res"},{"key":"164_CR66","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s40272-019-00372-4","volume":"22","author":"AE Horace","year":"2020","unstructured":"Horace AE, Golchin N, Knight EMP, Dawson NV, Ma X, Feinstein JA, et al. A scoping review of medications studied in pediatric polypharmacy research. Paediatr Drugs. 2020;22:85\u201394.","journal-title":"Paediatr Drugs"},{"key":"164_CR67","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1111\/epi.16382","volume":"60","author":"A Fechner","year":"2019","unstructured":"Fechner A, Hubert K, Jahnke K, Knake S, Konczalla J, Menzler K, et al. Treatment of refractory and superrefractory status epilepticus with topiramate: a cohort study of 106 patients and a review of the literature. Epilepsia. 2019;60:2448\u201358.","journal-title":"Epilepsia"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-020-00164-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-020-00164-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-020-00164-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T09:45:14Z","timestamp":1633513514000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-020-00164-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,6]]},"references-count":67,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["164"],"URL":"https:\/\/doi.org\/10.1007\/s43440-020-00164-5","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,6]]},"assertion":[{"value":"10 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have no conflict of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All animal experiments were approved by the Local Ethics Committee for Animal Experiments at the University of Life Sciences in Lublin, Poland, and complied with the ARRIVE guidelines and EU Directive 2010\/63\/EU for animal experiments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}